Dr. Deping Cheng

Biography

Deping Cheng, Ph.D. serves as Director of Bioanalysis at Alliance Pharma. He has more than 15 years of experience in the CRO and large pharmaceutical companies collaborating on global cross-company and integrated inter-company outsourcing and collaborative global projects. He has extensive experience in working with CRO organizations in evaluating, training, mentoring, monitoring bioanalytical and pharmacological method development and data interpretation of their operations from a scientific perspective. During his 10-year tenure at Johnson & Johnson, Dr. Cheng has played a significant role in the discovery and development of 7 marketed products in several therapeutic areas, such as SGLT1/2 inhibitor drug of Canagliflozin. In addition, during his work at J&J, he has been involved in several dozen projects during the lead discovery, lead optimization, and early development stages.  Dr. Cheng earned his Ph.D., M.S., and B.S. degrees in Analytical Chemistry from Zhejiang University in China. Following the completion of his doctorate degree, Dr. Cheng completed three successive post-doctoral appointments at San Francisco State University, the University of Oklahoma, and concurrently at both The Ohio State University College of Pharmacy and The Ohio State University Comprehensive Cancer Center. During his post-doctoral work, Dr. Cheng provided bioanalysis, drug metabolism, and pharmacokinetic support for preclinical and clinical studies in the areas of oncology and HIV.         Deping Cheng, Ph.D. serves as Director of Bioanalysis at Alliance Pharma. He has more than 15 years of experience in the CRO and large pharmaceutical companies collaborating on global cross-company and integrated inter-company outsourcing and collaborative global projects. He has extensive experience in working with CRO organizations in evaluating, training, mentoring, monitoring bioanalytical and pharmacological method development and data interpretation of their operations from a scientific perspective. During his 10-year tenure at Johnson & Johnson, Dr. Cheng has played a significant role in the discovery and development of 7 marketed products in several therapeutic areas, such as SGLT1/2 inhibitor drug of Canagliflozin. In addition, during his work at J&J, he has been involved in several dozen projects during the lead discovery, lead optimization, and early development stages.  Dr. Cheng earned his Ph.D., M.S., and B.S. degrees in Analytical Chemistry from Zhejiang University in China. Following the completion of his doctorate degree, Dr. Cheng completed three successive post-doctoral appointments at San Francisco State University, the University of Oklahoma, and concurrently at both The Ohio State University College of Pharmacy and The Ohio State University Comprehensive Cancer Center. During his post-doctoral work, Dr. Cheng provided bioanalysis, drug metabolism, and pharmacokinetic support for preclinical and clinical studies in the areas of oncology and HIV.        

Research Interest

Host defense mechanisms,LPS effects on neurotransmitters